illustration of a heart and an arrhythmia rhythm

Prioritizing Discovery and Advancements in Arrhythmia Therapies

June 11 - 13 , 2024
12:00 p.m. - 5:00 p.m. ET


Cardiac arrhythmias affect about 5% of the U.S. population and are a major cause of morbidity and mortality resulting in more than 250,000 deaths annually in the U.S. Arrhythmias can be paroxysmal and may present without symptoms leading them to be undetected and underdiagnosed in patients [e.g., atrial fibrillation], making their true prevalence difficult to assess. Since atrial fibrillation (AF) is often first detected after a stroke or after development of left ventricular dysfunction, it is associated with substantial mortality and morbidity, posing a significant burden to patients and health care services. Heart failure (HF) and AF may present in tandem, as AF may more likely precede than follow HF. Ventricular arrhythmia incidence increases with age and is higher in women. Despite a tremendous amount of research funding and resources dedicated to arrhythmia research and anti-arrhythmia therapies, there remains a significant unmet need for novel approaches to arrhythmia management.

There is an urgent need for developing rational strategies employing modern tools and approaches for the application of detection and treatment strategies in the face of competing risks from comorbidities. Additionally, there is very limited understanding on the aspects of social determinants of health (SDOH), age, and gender-based differences in arrhythmia prognosis. A better classification on subsets of arrhythmia patients is needed. This proposed workshop aims to provide a platform for robust discussions on both established and new research, explore knowledge gaps and barriers to translational progress, and tailor and optimize preventive, diagnostic, and treatment strategies at the individual patient level. The goal is to identify new directions in therapeutic approaches inclusive of pharmacologic management (novel drug targets, biomarkers etc.) and invasive techniques, discuss the potential use of artificial intelligence/eHealth-based tools (including SDOH, age, and sex-based differences) as it relates to arrhythmia prognosis and risk stratification, and their impact on morbidity and mortality from cardiovascular diseases across the lifespan.


View the agenda.

Workshop Goals and Objectives

  • Identify novel basic science research findings that are ready for translation into clinical research.
  • Identify new directions in therapeutic approaches, including pharmacologic management (novel drug targets, biomarkers etc.) and invasive techniques.
  • Develop strategies for use of artificial intelligence and eHealth-based tools.

Virtual Registration will close: June 4, 2024, at 12 PM EST.